Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia

References

• Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, 2nd edn. Am J Psychiatry 2004;161(2 Suppl):1-56
   PubMed Web of Science ®Google Scholar
• Kane JM, Correll CU. Pharmacologic treatment of schizophrenia. Dialogues Clin Neurosci 2010;12:345-57
   PubMedGoogle Scholar
• Falloon IR. Relapse: a reappraisal of assessment of outcome in schizophrenia. Schizophr Bull 1984;10:293-9
   PubMed Web of Science ®Google Scholar
• Burns T, Fiander M, Audini B. A delphi approach to characterising ‘relapse’ as used in UK clinical practice. Int J Soc Psychiatry 2000;46:220-30
   PubMed Web of Science ®Google Scholar
• Hui C. Relapse in schizophrenia. Hong Kong Med Diary 2011;16:8-9
   Google Scholar
• Olivares JM, Peuskens J, Pecenak J, et al. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Curr Med Res Opin 2009;25:2197-206
   PubMed Web of Science ®Google Scholar
• Simpson GM. Atypical antipsychotics and the burden of disease. Am J Manag Care 2005;11(8 Suppl):S235-41
   PubMed Web of Science ®Google Scholar
• Valenstein M, Blow FC, Copeland LA, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull 2004;30:255-64
   PubMed Web of Science ®Google Scholar
• Masand PS, Narasimhan M. Improving adherence to antipsychotic pharmacotherapy. Curr Clin Pharmacol 2006;1:47-56
   PubMedGoogle Scholar
• Olivares JM, Rodriguez-Morales A, Diels J, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009;24:287-96
   PubMed Web of Science ®Google Scholar
• Haddad PM, Taylor M, Niaz OS. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies. Br J Psychiatry Suppl 2009;52:S20-8
   PubMedGoogle Scholar
• McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry 2006;67(Suppl 5):15-18
   PubMed Web of Science ®Google Scholar
• Rosenheck RA, Krystal JH, Lew R, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med 2011;364:842-51
   PubMed Web of Science ®Google Scholar
• Kirson NY, Weiden PJ, Yermakov S, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry 2013;74:568-75
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Nitta M, Borenstein M, et al. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 2013;74:957-65
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull 2013;40:192-213
   Web of Science ®Google Scholar
• Fusar-Poli P, Kempton MJ, Rosenheck RA. Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Int Clin Psychopharmacol 2013;28:57-66
   PubMed Web of Science ®Google Scholar
• Taylor M, Currie A, Lloyd K, et al. Impact of risperidone long acting injection on resource utilization in psychiatric secondary care. J Psychopharmacol 2008;22:128-31
   PubMed Web of Science ®Google Scholar
• Su K-P, Chang H-C, Tsai S-J, et al. Relapse and long-acting injectable risperidone: a 1-year mirror image study with a national claims database in Taiwan. Value Health 2009;12(Suppl 3):S118-21
   PubMedGoogle Scholar
• Fernandez-Miranda J, Caramés-García V, Sánchez-García A. Tolerability and adherence of risperidone long acting injectable (RLAI) in severe schizophrenic patients. In: Americian Psychiatric Association (APA). San Francisco, 16--21 May 2009. Abstract no. NR6-040. 2009
   Google Scholar
• Apiquian R, Córdoba R, Louzã M. Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the electronic schizophrenia treatment adherence registry in Latin America. Neuropsychiatr Dis Treat 2010;7:19-26
   PubMed Web of Science ®Google Scholar
• Ren XS, Crivera C, Sikirica M, et al. Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration. J Clin Pharm Ther 2011;36:383-9
   PubMed Web of Science ®Google Scholar
• Willis M, Svensson M, Löthgren M, et al. The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden. Eur J Health Econ 2010;11:585-94
   PubMed Web of Science ®Google Scholar
• Kozma CM, Slaton T, Dirani R, et al. Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE). Curr Med Res Opin 2011;27:1603-11
   PubMed Web of Science ®Google Scholar
• Koczerginski D, Arshoff L. Hospital resource use by patients with schizophrenia: reduction after conversion from oral treatment to risperidone long-acting injection. Healthc Q 2011;14:82-7
   PubMedGoogle Scholar
• Lambert T, Olivares JM, Peuskens J, et al. Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium. Ann Gen Psychiatry 2011;10:10
   PubMed Web of Science ®Google Scholar
• Hosák L, Bahbouh R. Costs and outcomes of risperidone treatment in schizophrenia in the Czech Republic. Eur Psychiatry 2002;17:213-21
   PubMed Web of Science ®Google Scholar
• Hayhurst KP, Brown P, Lewis SW. The cost-effectiveness of clozapine: a controlled, population-based, mirror-image study. J Psychopharmacol 2002;16:169-75
   PubMed Web of Science ®Google Scholar
• Karagianis JL, LeDrew KK, Walker DJ. Switching treatment-resistant patients with schizophrenia or schizoaffective disorder to olanzapine: a one-year open-label study with five-year follow-up. Curr Med Res Opin 2003;19:473-80
   PubMed Web of Science ®Google Scholar
• Ren XS, Lee AF, Huang Y-H, et al. Initiation of atypical antipsychotic agents and health outcomes in patients with schizophrenia. J Clin Pharm Ther 2004;29:471-81
   PubMed Web of Science ®Google Scholar
• Alessi-Severini S, Honcharik PL, Simpson KD, et al. Evaluation of an interchangeability switch in patients treated with clozapine: a retrospective review. J Clin Psychiatry 2006;67:1047-54
   PubMed Web of Science ®Google Scholar
• Taylor D, Hayhurst K, Kerwin R. A controlled, mirror-image study of second-generation antipsychotics in the treatment of schizophrenia. Int Clin Psychopharmacol 2007;22:133-6
   PubMed Web of Science ®Google Scholar
• Yu AP, Atanasov P, Ben-Hamadi R, et al. Resource utilization and costs of schizophrenia patients treated with olanzapine versus quetiapine in a Medicaid population. Value Health 2009;12:708-15
   PubMed Web of Science ®Google Scholar
• Nyakyoma K, Morriss R. Effectiveness of clozapine use in delaying hospitalization in routine clinical practice: a 2 year observational study. Psychopharmacol Bull 2010;43:67-81
   PubMed Web of Science ®Google Scholar
• Asseburg C, Willis M, Löthgren M, et al. Hospitalisation utilisation and costs in schizophrenia patients in finland before and after initiation of risperidone long-acting injection. Schizophr Res Treatment 2012;2012:791468
   PubMedGoogle Scholar
• Kane JM, Sanchez R, Zhao J, et al. Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia. J Med Econ 2013;16:917-25
   PubMedGoogle Scholar
• Dubois V, Peuskens J, Geerts P, et al. Clinical outcomes of long-acting risperidone in recent versus long-term diagnosed Belgian schizophrenic patients: results from electronic Schizophrenia Treatment Adherence Registry (e-STAR) and Trial for the Initiation and Maintenance Of REmission in Schizophrenia with risperidone (TIMORES). Early Interv Psychiatry 2014;8:39-49
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
   PubMed Web of Science ®Google Scholar
• Tavcar R, Dernovsek MZ, Zvan V. Choosing antipsychotic maintenance therapy – a naturalistic study. Pharmacopsychiatry 2000;33:66-71
   PubMed Web of Science ®Google Scholar
• Hamilton SH, Edgell ET, Revicki DA, et al. Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. Int Clin Psychopharmacol 2000;15:245-55
   PubMed Web of Science ®Google Scholar
• Gaertner I, Gaertner HJ, Vonthein R, et al. Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study. J Clin Psychopharmacol 2001;21:305-10
   PubMed Web of Science ®Google Scholar
• Rabinowitz J, Lichtenberg P, Kaplan Z, et al. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 2001;158:266-9
   PubMed Web of Science ®Google Scholar
• Drew LRH, Griffiths KM, Hodgson DM. A five year follow-up study of the use of clozapine in community practice. Aust NZ J Psychiatry 2002;36:780-6
   PubMed Web of Science ®Google Scholar
• Patel NC, Dorson PG, Edwards N, et al. One-year rehospitalization rates of patients discharged on atypical versus conventional antipsychotics. Psychiatr Serv 2002;53:891-3
   PubMed Web of Science ®Google Scholar
• Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16-22
   PubMed Web of Science ®Google Scholar
• De Sena EP, Santos-Jesus R, Miranda-Scippa A, et al. Relapse in patients with schizophrenia: a comparison between risperidone and haloperidol. Rev Bras Psiquiatr 2003;25:220-3
   PubMedGoogle Scholar
• Conley RR, Kelly DL, Love RC, et al. Rehospitalization risk with second-generation and depot antipsychotics. Ann Clin Psychiatry 2003;15:23-31
   PubMedGoogle Scholar
• Kelly DL, Gale EA, Conley RR. Clozapine treatment in patients with prior substance abuse. Can J Psychiatry 2003;48:111-14
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Zhu B, Faries D, et al. A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia. Ann Gen Hosp Psychiatry 2004;3:11
   PubMedGoogle Scholar
• Gianfrancesco F, Wang R, Pesa J. Relationship between initial quetiapine dose and effectiveness as reflected in subsequent mental health service use among patients with schizophrenia or bipolar disorder. Value Health 2005;8:471-8
   PubMed Web of Science ®Google Scholar
• Moeller KE, Shireman TI, Liskow BI. Relapse rates in patients with schizophrenia receiving aripiprazole in comparison with other atypical antipsychotics. J Clin Psychiatry 2006;67:1942-7
   PubMed Web of Science ®Google Scholar
• Tunis SL, Faries DE, Nyhuis AW, et al. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial. Value Health 2006;9:77-89
   PubMed Web of Science ®Google Scholar
• Williams R, Kopala L, Malla A, et al. Medication decisions and clinical outcomes in the Canadian National Outcomes Measurement Study in Schizophrenia. Acta Psychiatr Scand Suppl 2006;430:12-21
   PubMedGoogle Scholar
• Xiang Y-Q, Zhang Z-J, Weng Y-Z, et al. Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia. Schizophr Res 2006;83:201-10
   PubMed Web of Science ®Google Scholar
• Ward A, Ishak K, Proskorovsky I, et al. Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: a retrospective database study. Clin Ther 2006;28:1912-21
   PubMed Web of Science ®Google Scholar
• Lin C-H, Lin S-C, Chen M-C, et al. Comparison of time to rehospitalization among schizophrenic patients discharged on typical antipsychotics, clozapine or risperidone. J Chinese Med Assoc 2006;69:264-9
   PubMedGoogle Scholar
• de Castro APW, Elkis H. Rehospitalization rates of patients with schizophrenia discharged on haloperidol, risperidone or clozapine. Rev Bras Psiquiatr 2007;29:207-12
   PubMed Web of Science ®Google Scholar
• Rouillon F, Chartier F, Gasquet I. Strategies of treatment with olanzapine in schizophrenic patients during stable phase: results of a pilot study. Eur Neuropsychopharmacol 2008;18:646-52
   PubMed Web of Science ®Google Scholar
• Kane JM, Lauriello J, Laska E, et al. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol 2008;28(2 Suppl 1):S29-35
   PubMed Web of Science ®Google Scholar
• Stargardt T, Weinbrenner S, Busse R, et al. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care. J Ment Health Policy Econ 2008;11:89-97
   PubMed Web of Science ®Google Scholar
• Herceg M, Jukić V, Vidović D, et al. Two-year rehospitalization rates of patients with newly diagnosed or chronic schizophrenia on atypical or typical antipsychotic drugs: retrospective cohort study. Croat Med J 2008;49:215-23
   PubMed Web of Science ®Google Scholar
• Taylor M, Shajahan P, Lawrie SM. Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study. J Clin Psychiatry 2008;69:240-5
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim D, Marder SR. Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:984-8
   PubMed Web of Science ®Google Scholar
• Peuskens J, Gillain B, De Graeve D, et al. Belgian Schizophrenia Outcome Survey – results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol. Eur Psychiatry 2009;24:154-63
   PubMed Web of Science ®Google Scholar
• Kozma CM, Dirani RG, Canuso CM, et al. Predicting hospital admission and discharge with symptom or function scores in patients with schizophrenia: pooled analysis of a clinical trial extension. Ann Gen Psychiatry 2010;9:24
   PubMed Web of Science ®Google Scholar
• Strom BL, Eng SM, Faich G, et al. Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Am J Psychiatry 2011;168:193-201
   PubMed Web of Science ®Google Scholar
• Chue P, Llorca P-M, Duchesne I, et al. Hospitalization rates in patients during long-term treatment with long-acting risperidone injection. J Appl Res 2005;5:266-74
   Google Scholar
• Simpson GM, Mahmoud RA, Lasser RA, et al. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2006;67:1194-203
   PubMed Web of Science ®Google Scholar
• Beauclair L, Chue P, McCormick J, et al. Impact of risperidone long-acting injectable on hospitalisation and medication use in Canadian patients with schizophrenia. J Med Econ 2007;10:427-42
   Google Scholar
• Fuller M, Shermock K, Russo P, et al. Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System. J Med Econ 2009;12:317-24
   PubMedGoogle Scholar
• Werneck AP, Hallak JC, Nakano E, et al. Time to rehospitalization in patients with schizophrenia discharged on first generation antipsychotics, non-clozapine second generation antipsychotics, or clozapine. Psychiatry Res 2011;188:315-19
   PubMed Web of Science ®Google Scholar
• Lammers L, Zehm B, Williams R. Risperidone long-acting injection in schizophrenia spectrum illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada. BMC Psychiatry 2013;13:155
   PubMed Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Xu J, et al. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr Res 2013;147:95-102
   PubMed Web of Science ®Google Scholar
• Burns T. Evolution of outcome measures in schizophrenia. Br J Psychiatry 2007;191:s1-6
   PubMed Web of Science ®Google Scholar
• Olfson M, Ascher-Svanum H, Faries DE, et al. Predicting psychiatric hospital admission among adults with schizophrenia. Psychiatr Serv 2011;62:1138-45
   PubMed Web of Science ®Google Scholar
• Mortensen PB, Eaton WW. Predictors for readmission risk in schizophrenia. Psychol Med 2009;24:223
   Web of Science ®Google Scholar
• Faries DE, Nyhuis AW, Ascher-Svanum H. Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example. Cost Eff Resour Alloc 2009;7:11
   PubMedGoogle Scholar
• Gianfrancesco F, Wang R-H, Mahmoud R, et al. Methods for claims-based pharmacoeconomic studies in psychosis. Pharmacoeconomics 2002;20:499-511
   PubMed Web of Science ®Google Scholar
• Silverman SL. From randomized controlled trials to observational studies. Am J Med 2009;122:114-20
   PubMed Web of Science ®Google Scholar
• Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887-92
   PubMed Web of Science ®Google Scholar
• Shrier I, Boivin J-F, Steele RJ, et al. Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles. Am J Epidemiol 2007;166:1203-9
   PubMed Web of Science ®Google Scholar
• Nicholl D, Akhras KS, Diels J, et al. Burden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspective. Curr Med Res Opin 2010;26:943-55
   PubMed Web of Science ®Google Scholar
• Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005;66:1122-9
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419-29
   PubMed Web of Science ®Google Scholar
• Achilla E, McCrone P. The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations. Appl Health Econ Health Policy 2013;11:95-106
   PubMedGoogle Scholar